CTLA4 and neoplasm: Numerous strategies targeting TME have been developed and have achieved considerable treatment efficacy, such as anti-angiogenesis therapy and harnessing effective immune components for elimination of neoplasms, mainly through blockage of immune checkpoints, including PD-1, PD-L1, and CTLA4.